MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-10-2026
Cullinan Management Current Ratio 2011-2026 | CGEM
Annual Current Ratio Cullinan Management
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.3 | 19.7 | 16 | 21.5 | 37 | 14.8 | 39.7 | 25.8 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 39.7 | 11.3 | 23.2 |
Quarterly Current Ratio Cullinan Management
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.8 | 18.5 | 20.8 | 19.7 | 25.7 | 27.2 | 18.9 | 16 | 19.1 | 23.3 | 17.6 | 21.5 | 19.8 | 10.7 | 24.3 | 37 | 57.2 | 79.9 | 48.1 | 14.9 | 14.9 | 14.9 | 14.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 79.9 | 10.7 | 25.2 |
Current Ratio of other stocks in the Biotechnology industry
| Issuer | Current Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aquestive Therapeutics
AQST
|
0.827 | $ 4.12 | -0.36 % | $ 441 M |  USA |
 |
MorphoSys AG
MOR
|
1.02 | - | 2.43 % | $ 254 M |  Germany |
 |
Arcturus Therapeutics Holdings
ARCT
|
4.74 | $ 8.32 | 3.67 % | $ 228 M |  Israel |
 |
Arcutis Biotherapeutics
ARQT
|
1.78 | $ 23.65 | 0.08 % | $ 3.01 B | USA |
 |
BioVie
BIVI
|
8.46 | $ 1.46 | 2.82 % | $ 2.16 M | USA |
 |
BioLineRx Ltd.
BLRX
|
1.53 | $ 2.32 | 4.98 % | $ 908 M | Israel |
 |
BioNTech SE
BNTX
|
7.95 | $ 91.44 | 0.29 % | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
8.96 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.59 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
0.922 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
1.34 | - | -13.47 % | $ 169 M | France |
 |
BioXcel Therapeutics
BTAI
|
0.32 | $ 1.16 | -2.12 % | $ 14.2 M | USA |
 |
Midatech Pharma plc
MTP
|
2.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.02 | - | -1.52 % | $ 24.7 M | USA |
 |
Burford Capital Limited
BUR
|
2.14 | $ 4.52 | 9.18 % | $ 683 M | Britain |
 |
Acorda Therapeutics
ACOR
|
1.61 | - | -24.86 % | $ 820 K | USA |
 |
Cabaletta Bio
CABA
|
3.11 | $ 3.1 | 4.56 % | $ 311 M | USA |
 |
Adverum Biotechnologies
ADVM
|
1.65 | - | - | $ 86.2 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.76 | $ 3.17 | 1.44 % | $ 6.9 B | Israel |
 |
Advaxis
ADXS
|
5.93 | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
2.31 | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
1.6 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
0.995 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
2.59 | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
12.4 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.79 | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
10.9 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
6.18 | - | 0.23 % | $ 488 M | USA |
 |
Catalyst Biosciences
CBIO
|
6.97 | $ 19.48 | 0.39 % | $ 1.74 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.04 | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
2.19 | - | 3.16 % | $ 1.9 M | USA |
 |
Codexis
CDXS
|
1.52 | $ 1.95 | 6.87 % | $ 170 M | USA |
 |
Alpine Immune Sciences
ALPN
|
2.67 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
3.34 | - | 10.36 % | $ 9.8 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
11.6 | $ 3.01 | 0.67 % | $ 257 M | USA |
 |
Cerus Corporation
CERS
|
1.41 | $ 1.91 | 2.69 % | $ 364 M | USA |
 |
Coherus BioSciences
CHRS
|
1.31 | $ 1.72 | -0.87 % | $ 201 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
3.57 | $ 0.46 | -13.02 % | $ 5.27 M | Israel |
 |
Aravive
ARAV
|
1.21 | - | -13.39 % | $ 1.45 M | USA |
 |
Aptose Biosciences
APTO
|
0.269 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
2.35 | - | -39.0 % | $ 4.57 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
2.1 | $ 2.25 | -0.44 % | $ 998 K | USA |
 |
CureVac N.V.
CVAC
|
2.47 | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
1.75 | - | - | $ 96.9 B | Britain |
 |
Catalyst Pharmaceuticals
CPRX
|
7.37 | $ 24.95 | 1.05 % | $ 3.05 B | USA |
 |
Celldex Therapeutics
CLDX
|
10.4 | $ 31.33 | 0.85 % | $ 2.08 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
8.13 | $ 10.27 | 0.98 % | $ 137 M | USA |
 |
Cardiff Oncology
CRDF
|
3.75 | $ 1.6 | 1.27 % | $ 107 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.67 | - | -52.27 % | $ 4.45 M | USA |